The cost of drug development has drastically increased to >$1 billion contributing to a decline in the productivity of the pharmaceutical industry. This opens up opportunities for biotech companies like iCellVivo, Inc. to develop next-generation interacting multiple human organ test systems for drug discovery, toxicity testing and 3d stem cell assays potentially reducing the need for animal testing. iCellVivo, Inc. is developing a 6-well based multiorgan platform with integrated electrophysiological assay to improve clinical predictability and reduce animal testing. This patent pending portable, open-well configuration multiorgan platform uses microfluidic plate and 3-D inserts for standard well-plates to perform preclinical toxicity profiling.